Featured Press Releases

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

Phanes Therapeutics

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

  • 03 Dec 2024

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug...

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive Alzheimer’s Biomarker Detection

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive Alzheimer’s Biomarker Detection

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

  • Menarini Industrie Farmaceutiche Riunite
  • 25 Nov 2025
Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

  • Eisai Inc.
  • 25 Nov 2025
VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

  • Intuitive Ventures
  • 19 Nov 2025
FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

  • Arrowhead Pharmaceuticals, Inc.
  • 19 Nov 2025
Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

  • Emulate, Inc. and FUJIFILM Cellular Dynamics
  • 18 Nov 2025
Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.